MARKET

PCVX

PCVX

Vaxcyte, Inc.
NASDAQ
58.38
-0.12
-0.21%
After Hours: 57.22 -1.16 -1.99% 18:22 04/02 EDT
OPEN
57.42
PREV CLOSE
58.50
HIGH
58.78
LOW
56.83
VOLUME
1.02M
TURNOVER
--
52 WEEK HIGH
65.00
52 WEEK LOW
27.66
MARKET CAP
8.40B
P/E (TTM)
-10.3634
1D
5D
1M
3M
1Y
5Y
1D
Vaxcyte (PCVX) Valuation Check As VAX-31 Phase 3 OPUS Trials Reach Full Enrollment
Simply Wall St · 1d ago
Vaxcyte COO Jim Wassil disposes of common shares worth $0.1 million
Reuters · 2d ago
Should Vaxcyte’s (PCVX) Fully Enrolled VAX-31 Phase 3 Trials Prompt a Portfolio Reassessment?
Simply Wall St · 6d ago
Weekly Report: what happened at PCVX last week (0323-0327)?
Weekly Report · 6d ago
Notable Wednesday Option Activity: PCVX, MRVL, CORT
NASDAQ · 03/25 19:28
Vera Therapeutics appoints Jane Wright-Mitchell chief legal officer
Reuters · 03/25 11:30
Mizuho Securities Sticks to Its Buy Rating for Vaxcyte (PCVX)
TipRanks · 03/24 15:15
Vaxcyte completes enrollment in Vaxcyte VAX-31 OPUS-1 trial
TipRanks · 03/23 13:06
More
About PCVX
Vaxcyte Inc. is a clinical-stage vaccine innovation company. The Company is engaged in developing spectrum conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its pipeline includes VAX-31, a 31-valent PCV candidate advancing to a Phase III adult clinical program and being evaluated in a Phase II infant clinical program, which is being developed for the prevention of invasive pneumococcal disease (IPD) in adults and infants and is the broadest-spectrum pneumococcal conjugate vaccine (PCV) candidate in the clinic. VAX-24, the Company’s 24-valent PCV candidate, is designed to cover more serotypes than any infant PCV on-market and is being evaluated in a Phase II infant study. Its pipeline also includes VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections; VAX-PG, a therapeutic vaccine candidate designed to slow or stop the progression of periodontal disease; and VAX-GI, a vaccine candidate designed to prevent Shigella.

Webull offers Vaxcyte Inc stock information, including NASDAQ: PCVX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PCVX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PCVX stock methods without spending real money on the virtual paper trading platform.